Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, Y., Morse, M., … Hurwitz, H. (2016). Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL). In Journal of Clinical Oncology (Vol. 34, pp. e15013–e15013). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.e15013

Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).” In Journal of Clinical Oncology, 34:e15013–e15013. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e15013.

Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar Y, Morse M, et al. Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. e15013–e15013.

Clarke, Jeffrey Melson, et al. “Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. e15013–e15013. Crossref, doi:10.1200/jco.2016.34.15_suppl.e15013.

Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar Y, Morse M, Dropkin E, Howard L, O’Neill M, Rushing CN, Niedzwiecki D, Watson H, Arrowood C, Hurwitz H. Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. e15013–e15013.